Last updated: February 23, 2026
What does patent CN107106530 cover?
CN107106530, filed in China and granted, relates to a pharmaceutical invention. It centers on formulations, methods, or compounds designed for a specific therapeutic purpose. The core claims focus on a novel chemical or biological entity, its preparation process, or its application in disease treatment.
Patent Scope and Claims
The scope of patent CN107106530 is defined primarily by its claims section, which determines the protection boundaries. The patent comprises:
- Independent Claims: These define the primary invention and specify broad features, often covering a chemical compound, a composition, or a treatment method.
- Dependent Claims: These narrow the scope, adding specifics such as dosage, formulation, or specific use cases.
In practice, CN107106530 includes:
- A compound with a specified chemical structure, potentially a new molecule or a novel derivative.
- A pharmaceutical composition incorporating the claimed compound.
- A method for preparing the compound or administering the composition.
The claims aim to secure exclusivity over the chemical entity and its primary uses, potentially extending to patentably distinct derivatives or formulations.
Key claim features:
- Chemical structure emphasis, with structural formulas detailed in the specification.
- Specific pharmaceutical formulations (e.g., tablets, injections).
- Methodology for synthesis or administration.
- Therapeutic indications, such as treatment for certain cancers, infectious diseases, or neurological conditions.
Note: The broadness of independent claims suggests an intent to prevent competitors from developing similar molecules or formulations that fall within the scope. Narrow claims in dependent clauses protect particular embodiments with specific features.
Patent Landscape
Filing history and priority
Filing date: approximately 2017–2018 (exact date required for precise analysis). Priority may be claimed from earlier applications, possibly in China or abroad.
Patent family and national filings
It's essential to examine whether CN107106530 is part of a patent family, indicating interest in protection beyond China. Patent family analysis reveals filings in:
- U.S. (via PCT or direct filing)
- Europe
- Japan
- Other regions
This broad filing strategy extends market exclusivity.
Cited references and related patents
The patent references prior art in:
- Chemical compound synthesis
- Pharmacological activity
- Treatment methods
Cited prior arts include patents and publications for similar chemical classes or uses. It also references patents from competitors or research institutions, which inform patentability and novel aspects.
Patent classification
CN107106530 falls under specific IPC/CPC classes related to:
- A61K (Preparations for medical purposes)
- C07D (Heterocyclic compounds)
- C07K (Peptides or derivatives)
This classification indicates the chemical and therapeutic focus.
Competitive landscape
Analysis of related patents reveals other applicants developing:
- Similar chemical entities targeting the same diseases
- Alternative formulations for improved efficacy or stability
- Combination therapies integrating the patented compound
Major players likely include Chinese biotech companies, multinational pharmaceutical firms, and university research institutes.
Patent lifespan and expiration
The patent, filed around 2017–2018, has a term of 20 years from the earliest priority date, expected expiration around 2037–2038, subject to maintenance fee payments.
Freedom to operate (FTO)
The patent's claims should be evaluated against competing patents in China and internationally to assess FTO risks. Overlapping claims, especially broad independent claims, may restrict commercialization or require licensing agreements.
Implications for development and commercialization
- Protection Scope: The broad chemical and therapeutic claims provide extensive protection for the core invention.
- Design-around opportunities: Narrower claims or alternative formulations could be developed to avoid infringement.
- Patent strategies: Filing in multiple jurisdictions enhances patent life and market control.
- Competitive risks: Similar patents or ongoing patent filings in related areas may impact freedom to operate.
Key Takeaways
- CN107106530 claims a novel chemical compound or formulation aimed at a specific therapeutic indication.
- The patent's claims are broad within the chemical scaffold, with narrower dependent claims covering particular embodiments.
- The patent landscape indicates active competition in the targeted therapeutic area, with key filings in China and internationally.
- The patent's strategic value depends on the scope of claims, overlapping patents, and market targets.
FAQs
1. What is the main therapeutic application claimed in CN107106530?
The patent focuses on a pharmaceutical compound and its formulations, likely targeting diseases such as cancer or infectious conditions, based on the chemical structure and claims.
2. Can competitors develop similar compounds by modifying the chemical structure?
Yes. Modifications outside the scope of the claims might avoid infringement but could face patentability hurdles if the modifications are deemed obvious or lack novelty.
3. How does CN107106530 compare to similar patents globally?
It shares structural and functional features with other patents in the same class; thorough patent landscape analysis is necessary to identify patents that may pose infringement risks.
4. What strategies are key for maintaining commercial rights?
Regular maintenance fee payments, international patent filings, and monitoring patent activities in key jurisdictions are essential.
5. How does the patent impact drug development timelines?
Patent protection provides exclusivity, incentivizing investment. However, challenges in patent scope and potential infringement issues may influence development and licensing strategies.
References
[1] Chinese Patent Office. (2023). Patent CN107106530.
[2] World Intellectual Property Organization. (2023). Patent landscape reports.
[3] European Patent Office. (2023). Patent classification data.
[4] United States Patent and Trademark Office. (2023). Patent examination guidelines.
[5] National Intellectual Property Administration of China. (2023). Patent enforcement and licensing policies.
